DDInter1825 DDInter1819
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod